KPV vs LL-37
Updated September 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of KPV and LL-37 (also searched as LL-37 vs KPV) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
KPV centers on healing, while LL-37 leans toward healing. On indexed research, LL-37 is ahead (KPV: 22 studies, Human evidence; LL-37: 32, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •KPV is strongest for healing; LL-37 for healing.
- •Evidence: KPV Human evidence (22 studies) vs LL-37 Human evidence (32).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
KPV vs LL-37: side-by-side
| Metric | KPV | LL-37 |
|---|---|---|
| Class | Healing | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 22 | 32 |
| Research level | Preclinical | Well Studied |
| Strongest effect | Healing & recovery | Healing & recovery |
| Healing & recovery | 4.0▲ | 4.0▲ |
| Muscle & body comp | 1.0▲ | 1.0▲ |
| Metabolic & appetite | 1.0 | 2.0▲ |
| Neuro & mood | 1.0▲ | 1.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 4.0▲ | 4.0▲ |
| Skin & aesthetics | 2.0▲ | 2.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | KPV | LL-37 |
|---|---|---|
| Mechanism | Modulation of inflammatory responses | Disrupts microbial membranes, leading to cell lysis |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is KPV?
KPV is a tripeptide composed of lysine, proline, and valine, which has been studied for its potential immunomodulatory and wound healing properties. Its mechanism of action is thought to involve the modulation of inflammatory responses, potentially through the inhibition of pro-inflammatory cytokines and promotion of anti-inflammatory pathways. KPV may also enhance the healing process by promoting angiogenesis and fibroblast proliferation, which are critical for tissue repair.
Full KPV profile, mechanism & studies →What is LL-37?
LL-37 is a human cathelicidin antimicrobial peptide that plays a significant role in the innate immune response. It exhibits a range of biological activities, including antimicrobial, immunomodulatory, and wound healing properties. LL-37 is produced by various cells, including epithelial cells and neutrophils, and is known to interact with a variety of pathogens, including bacteria, viruses, and fungi.
Full LL-37 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~4.0/5 |
| Muscle | Even | Both ~1.0/5 |
| Metabolic | LL-37 | 2.0/5 effect signal |
| Neuro | Even | Both ~1.0/5 |
| Inflammation | Even | Both ~4.0/5 |
| Skin | Even | Both ~2.0/5 |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack KPV and LL-37?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
KPV vs LL-37: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
KPV has 22 approved studies indexed (Human evidence), and LL-37 has 32 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is KPV or LL-37 better?
It depends on your goal. KPV is strongest for healing; LL-37 for healing. LL-37 has more indexed studies (32). See the goal-by-goal breakdown above.
Is KPV or LL-37 better for weight loss?
LL-37 shows the stronger metabolic & appetite profile (2.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is KPV or LL-37 better for muscle?
Both land close on the muscle & body-composition axis.
Which has more research, KPV or LL-37?
KPV has 22 approved studies indexed (Human evidence); LL-37 has 32 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack KPV and LL-37?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of KPV vs LL-37?
KPV: no community-reported effects logged yet. LL-37: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is KPV or LL-37 FDA-approved?
KPV is a research-use compound and is not FDA-approved. LL-37 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is LL-37 better than KPV?
For healing, LL-37 has the edge; for healing, KPV does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
KPV and LL-37 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 21, 2026.